Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Beam Therapeutics Inc (NASDAQ: BEAM) closed at $25.69 in the last session, down -9.80% from day before closing price of $28.48. In other words, the price has decreased by -$9.80 from its previous closing price. On the day, 8.84 million shares were traded.
Ratios:
We take a closer look at BEAM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.82 and its Current Ratio is at 4.82. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Leerink Partners Upgraded its Market Perform to Outperform on November 06, 2024, whereas the target price for the stock was revised from $27 to $39.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 18 ’25 when Cavanagh Bethany J sold 6,287 shares for $35.00 per share. The transaction valued at 220,045 led to the insider holds 37,527 shares of the business.
Bellon Christine sold 10,000 shares of BEAM for $340,000 on Feb 14 ’25. The Chief Legal Officer now owns 102,968 shares after completing the transaction at $34.00 per share. On Feb 14 ’25, another insider, CHRISTINE BELLON, who serves as the Officer of the company, bought 10,000 shares for $34.00 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 33.85 while its Price-to-Book (P/B) ratio in mrq is 2.93.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $38.99, while it has fallen to a 52-week low of $20.84. The 50-Day Moving Average of the stock is -5.05%, while the 200-Day Moving Average is calculated to be -0.42%.
Shares Statistics:
A total of 83.63M shares are outstanding, with a floating share count of 73.69M. Insiders hold about 11.95% of the company’s shares, while institutions hold 83.36% stake in the company.
